LOXO-305 Comes Out Swinging In Battle Of BTK Inhibitors
Lilly's Loxo Presents Positive Phase I/II Data In MCL At ASH
Executive Summary
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.
You may also be interested in...
Keeping Track Of Rolling Submissions: Gamida Cell, Roche, Lilly And Reata Are Latest To Use Fast Track
Applications are underway for omidubicel, mosenutuzumab, pirtobrutinib and omaveloxolone.
After Lybalvi’s Solid Early Launch, Alkermes Touts Neuropsychiatry Potential
Alkermes tells J.P. Morgan audience it hopes new combo Lybalvi and established Aristada will boost each other and the neuropsychiatric franchise. But the firm noted its addiction drug Vivitrol requires complicated commercial plan.
Lilly’s 2021 Double-Digit Growth Comes From COVID-19 Drugs, New Products
Most of Lilly’s 2021 gains will come from its newer products, but sales of COVID-19 treatments added $500m to the company’s 2020 revenue guidance and may total $1bn-$2bn next year.